


Stereochemistry abstracts

Vinay V. Thakur and A. Sudalai*

Tetrahedron: Asymmetry 14 (2003) 407



(*R*)-(+)-Lansoprazole

Ee = 88%



$[\alpha]_D^{25} = +250.60$ (*c* 0.5, acetone)

Source of chirality: asymmetric synthesis

Absolute configuration: *R*

Rumiko Sakurai and Kenichi Sakai*

Tetrahedron: Asymmetry 14 (2003) 411



(*1R,2S*)-(+)-*cis*-1-Amino-2-indanol (*S*)-2-phenylpropionate

De >99%


$[\alpha]_D^{20} = +20.0$ (*c* 1.0, EtOH)

Source of chirality: resolution with chiral acid

Absolute configuration: 1*R*,2*S*

Jahyo Kang,* Tae Hyung Kim, Kyoung Han Yew and Wook Ki Lee

Tetrahedron: Asymmetry 14 (2003) 415



Di- μ -chlorobis[$(\eta^5-(S)-(R_p)-2-(2'-(4'-methyl ethyl)oxazolinyl) cyclopentadienyl, 1-C, 3'-N)-(\eta^4-tetraphenylcyclobutadiene)$] cobalt]dipalladium

Mp = 192–196°C (sublimation)


$[\alpha]_D^{23} = +1064$ (*c* = 0.25, CHCl₃)

$R_f = 0.39$ (20% Ethyl acetate/n-hexane)

Anal. calcd for $C_{78}H_{66}Co_2N_2O_2Cl_2Pd_2$: C, 61.9; H, 4.54; N, 1.91; Found: C, 60.3; H, 4.11; N, 1.67

Palakodety Radha Krishna,* B. Lavanya and G. V. M. Sharma

Tetrahedron: Asymmetry 14 (2003) 419




6-[2',2'-Dimethyl-(4'S)-1',3'-dioxolan-4'-yl]-3-methoxycarbonyloxy-2-phenyl-(2*R*,3*S*,4*S*,6*R*)-tetrahydro-2*H*-4-pyranyl acetate

$[\alpha]_D^{25} = +7.5$ (*c* 0.8, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2*R*,3*S*,4*S*,6*R*,4'S


 $C_{19}H_{26}O_6$

6-[2',2'-Dimethyl-(4'S)-1',3'-dioxolan-4'-yl]-3-methoxy-2-phenyl-(2S,3S,4R,6R)-tetrahydro-2H-4-pyranyl acetate

 $[\alpha]_D^{25} = -20.5$ (*c* 1.0, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2S,3S,4R,6R,4'S


 $C_{19}H_{26}O_6$

6-[2',2'-Dimethyl-(4'S)-1',3'-dioxolan-4'-yl]-4-methoxy-2-phenyl-(2S,3R,4S,6R)-tetrahydro-2H-3-pyranyl acetate

 $[\alpha]_D^{25} = -6.4$ (*c* 0.5, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: 2S,3R,4S,6R,4'S

 $C_{17}H_{21}NS$


(S)-N-Isopropyl-2-amino-2-phenyl-1-thiophenyl-ethane

Ee = 99%

 $[\alpha]_D^{20} = +7.8$ (*c* 1.03, CH₂Cl₂)

Source of chirality: (S)-phenylglycine

Absolute configuration: (S)

 $C_{13}H_{21}NS$


(S)-N-Isopropyl-2-amino-2-phenyl-1-thioethyl-ethane

Ee = 99%

 $[\alpha]_D^{20} = +90.0$ (*c* 1.12, CH₂Cl₂)

Source of chirality: (S)-phenylglycine

Absolute configuration: (S)

 $C_{18}H_{23}NS$


(S)-N-Isopropyl-2-amino-3-phenyl-1-thiophenyl-propane

Ee = 99%

 $[\alpha]_D^{20} = +5.3$ (*c* 1.22, CH_2Cl_2)

Source of chirality: (S)-phenylalanine

Absolute configuration: (S)

 $C_{14}H_{23}NS$


(S)-N-Isopropyl-2-amino-3-phenyl-1-thioethyl-propane

Ee = 99%

 $[\alpha]_D^{20} = +18.9$ (*c* 1.14, CH_2Cl_2)

Source of chirality: (S)-phenylalanine

Absolute configuration: (S)

 $C_{14}H_{23}NS$


(S)-N-Isopropyl-2-amino-3-methyl-1-thiophenyl-butane

Ee = 99%

 $[\alpha]_D^{20} = +30.0$ (*c* 0.96, CH_2Cl_2)

Source of chirality: (S)-valine

Absolute configuration: (S)

 $C_{14}H_{23}NS$


(S)-N-Isopropyl-2-amino-3-methyl-1-thioethyl-butane

Ee = 99%

 $[\alpha]_D^{20} = +38.5$ (*c* 0.96, CH_2Cl_2)

Source of chirality: (S)-valine

Absolute configuration: (S)



C₂₉H₃₀N₂O₅


(3R,4S,2'S,5'S,6'R)-1-(4-Methoxyphenyl)-4-phenyl-3-[(2',4',5'-trimethyl-3'-oxo-6'-phenylmorpholin-2'-yl)oxy]azetidin-2-one

D.e. >98%

[α]_D = -51.0 (*c* 0.9, CHCl₃)

Source of chirality: (-)-ephedrine

Absolute configuration: 3*R*,4*S*,2'*S*,5'*S*,6'*R*



C₂₉H₃₀N₂O₅


(3R,4S,2'S,5'S,6'R)-4-(4-Methoxyphenyl)-1-phenyl-3-[(2',4',5'-trimethyl-3'-oxo-6'-phenylmorpholin-2'-yl)oxy]azetidin-2-one

D.e. >97%

[α]_D = -64.4 (*c* 0.9, CHCl₃)

Source of chirality: (-)-ephedrine

Absolute configuration: 3*R*,4*S*,2'*S*,5'*S*,6'*R*



C₃₀H₃₂N₂O₆


(3R,4S,2'S,5'S,6'R)-1,4-Di-(4-methoxyphenyl)-3-[(2',4',5'-trimethyl-3'-oxo-6'-phenylmorpholin-2'-yl)oxy]azetidin-2-one

D.e. >97%

[α]_D = -78.5 (*c* 1.3, CHCl₃)

Source of chirality: (-)-ephedrine

Absolute configuration: 3*R*,4*S*,2'*S*,5'*S*,6'*R*



C₂₈H₂₈N₂O₄


(3R,4S,2'S,5'S,6'R)-1,4-Diphenyl-3-[(2',4',5'-trimethyl-3'-oxo-6'-phenylmorpholin-2'-yl)oxy]azetidin-2-one

D.e. >97%

[α]_D = -61.0 (*c* 1.0, CHCl₃)

Source of chirality: (-)-ephedrine

Absolute configuration: 3*R*,4*S*,2'*S*,5'*S*,6'*R*



$C_{29}H_{30}N_2O_5$


($3S,4R,2'S,5'S,6'R$)-1-(4-Methoxyphenyl)-4-phenyl-3-[(2',4',5'-trimethyl-3'-oxo-6'-phenylmorpholin-2'-yl)oxy]azetidin-2-one

D.e. >98%

$[\alpha]_D = -189.4$ (c 1.4, $CHCl_3$)

Source of chirality: (-)-ephedrine

Absolute configuration: $3S,4R,2'S,5'S,6'R$



$C_{29}H_{30}N_2O_5$


($3S,4R,2'S,5'S,6'R$)-4-(4-Methoxyphenyl)-1-phenyl-3-[(2',4',5'-trimethyl-3'-oxo-6'-phenylmorpholin-2'-yl)oxy]azetidin-2-one

D.e. >97%

$[\alpha]_D = -181.5$ (c 0.6, $CHCl_3$)

Source of chirality: (-)-ephedrine

Absolute configuration: $3S,4R,2'S,5'S,6'R$



$C_{30}H_{32}N_2O_6$


($3S,4R,2'S,5'S,6'R$)-1,4-Di-(4-methoxyphenyl)-3-[(2',4',5'-trimethyl-3'-oxo-6'-phenylmorpholin-2'-yl)oxy]azetidin-2-one

D.e. >97%

$[\alpha]_D = -170.9$ (c 2.0, $CHCl_3$)

Source of chirality: (-)-ephedrine

Absolute configuration: $3S,4R,2'S,5'S,6'R$



$C_{28}H_{28}N_2O_4$


($3S,4R,2'S,5'S,6'R$)-1,4-Diphenyl-3-[(2',4',5'-trimethyl-3'-oxo-6'-phenylmorpholin-2'-yl)oxy]azetidin-2-one

D.e. >97%

$[\alpha]_D = -194.6$ (c 1.5, $CHCl_3$)

Source of chirality: (-)-ephedrine

Absolute configuration: $3S,4R,2'S,5'S,6'R$



C₁₅H₁₉NO₅


(2S,5S,6R)-[(2,4,6-Trimethyl-3-oxo-6-phenylmorpholin-2-yl)oxy]acetic acid

D.e. >97%

[α]_D = -64.9 (*c* 0.9, CHCl₃)

Source of chirality: (-)-ephedrine

Absolute configuration: 2*S*,5*S*,6*R*



C₁₆H₁₅NO₃


(3*R*,4*S*)-1-(4-Methoxyphenyl)-4-phenyl-3-hydroxyazetidin-2-one

D.e. >99%

[α]_D = +180.0 (*c* 0.4, CHCl₃)

Source of chirality: synthesis

Absolute configuration: 3*R*,4*S*



C₁₆H₁₅NO₃


(3*S*,4*R*)-1-(4-Methoxyphenyl)-4-phenyl-3-hydroxyazetidin-2-one

D.e. >99%

[α]_D = -178.0 (*c* 0.9, CHCl₃)

Source of chirality: synthesis

Absolute configuration: 3*S*,4*R*



C₁₆H₁₅NO₃

(3*S*,4*R*)-4-(4-Methoxyphenyl)-1-phenyl-3-hydroxyazetidin-2-one

D.e. >99%


[α]_D = -173.7 (*c* 1.0, CHCl₃)

Source of chirality: synthesis

Absolute configuration: 3*S*,4*R*

Bidhan A. Shinkre, Vedavati G. Puranik, B. M. Bhawal
and A. R. A. S. Deshmukh*

Tetrahedron: Asymmetry 14 (2003) 453



(*3S,4R*)-1,4-Di-(4-methoxyphenyl)-3-hydroxyazetidin-2-one

D.e. >99%


$[\alpha]_D = -179.1$ (*c* 2.2, CHCl_3)

Source of chirality: synthesis

Absolute configuration: 3*S*,4*R*

Bidhan A. Shinkre, Vedavati G. Puranik, B. M. Bhawal
and A. R. A. S. Deshmukh*

Tetrahedron: Asymmetry 14 (2003) 453



(*3S,4R*)-1,4-Diphenyl-3-hydroxyazetidin-2-one

D.e. >99%


$[\alpha]_D = -188.4$ (*c* 0.9, CHCl_3)

Source of chirality: synthesis

Absolute configuration: 3*S*,4*R*

Tamara Danelli, Rita Annunziata, Maurizio Benaglia,*
Mauro Cinquini, Franco Cozzi and Graziella Tocco

Tetrahedron: Asymmetry 14 (2003) 461



PEG-supported *N*-(9-anthracenylmethyl)cinchoninium chloride


Ee = 100%

$[\alpha]_D^{23} = +3.3$ (*c* 0.8, CHCl_3)

Source of chirality: natural product

Tamara Danelli, Rita Annunziata, Maurizio Benaglia,*
Mauro Cinquini, Franco Cozzi and Graziella Tocco

Tetrahedron: Asymmetry 14 (2003) 461



PEG-supported quinine


Ee = 100%

$[\alpha]_D^{23} = -3.7$ (*c* 0.15, CHCl_3)

Source of chirality: natural product

Tamara Danelli, Rita Annunziata, Maurizio Benaglia,*
Mauro Cinquini, Franco Cozzi and Graziella Tocco

Tetrahedron: Asymmetry 14 (2003) 461




PEG-supported quinine benzoate

E.e.=100%
 $[\alpha]_D^{23}=+6.6$ (*c* 0.3, CHCl₃)
Source of chirality: natural product

Tamara Danelli, Rita Annunziata, Maurizio Benaglia,*
Mauro Cinquini, Franco Cozzi and Graziella Tocco

Tetrahedron: Asymmetry 14 (2003) 461




PEG-supported *N*-(9-anthracenylmethyl)quininium chloride

E.e.=100%
 $[\alpha]_D^{23}=-7.75$ (*c* 0.3, CHCl₃)
Source of chirality: natural product

M.-Lluïsa Bennasar,* Ester Zulaica, Yolanda Alonso and Joan Bosch


Tetrahedron: Asymmetry 14 (2003) 469








$[\alpha]_D^{22}=-187$ (*c* 1, CHCl₃)
Source of chirality: (S)-prolinol
Absolute configuration: *S*


M.-Lluïsa Bennasar,* Ester Zulaica, Yolanda Alonso and Joan Bosch

Tetrahedron: Asymmetry 14 (2003) 469



$[\alpha]_D^{22}=-98$ (*c* 1, CHCl₃)
Source of chirality: (S)-prolinol
Absolute configuration: *S*


1-Benzyl-3-[(2*S*)-(methoxymethyl)pyrrolidinylcarbonyl]pyridinium bromide $[\alpha]_D^{22} = -106$ (*c* 1.7, CHCl₃)Source of chirality: (*S*)-prolinolAbsolute configuration: *S*(R)-4-Butyl-3-[(2*S*)-(methoxymethyl)pyrrolidinylcarbonyl]-1-methyl-5-(trichloroacetyl)-1,4-dihydropyridine(S)-3-(Methoxycarbonyl)-5-[(2*S*)-(methoxymethyl)pyrrolidinylcarbonyl]-1-methyl-4-phenyl-1,4-dihydropyridine $[\alpha]_D^{22} = +25$ (*c* 1, CHCl₃)Source of chirality: (*S*)-prolinolAbsolute configuration: 4*S*,2'*S*(S)-4-Butyl-3-(methoxycarbonyl)-5-[(2*S*)-(methoxymethyl)pyrrolidinylcarbonyl]-1-methyl-1,4-dihydropyridine $[\alpha]_D^{22} = -64$ (*c* 1.3, CHCl₃)Source of chirality: (*S*)-prolinolAbsolute configuration: 4*S*,2'*S*

 $C_{16}H_{24}N_2O_4$


(S)-3-(Methoxycarbonyl)-5-[(2S)-(methoxymethyl)pyrrolidinylcarbonyl]-1,4-dimethyl-1,4-dihydropyridine

 $[\alpha]_D^{22} = -110$ (*c* 1.5, CHCl₃)


Source of chirality: (S)-prolinol

Absolute configuration: 4*S*,2'S $C_{24}H_{29}N_3O_3$ (1*R*,5*S*)-4-[(2*S*)-(Methoxymethyl)pyrrolidinylcarbonyl]-2,8-dimethyl-7-oxo-2,5,6,7-tetrahydro-1*H*-1,5-methanoazonino[4,3-*b*]indole $[\alpha]_D^{22} = -264$ (*c* 0.5, CHCl₃)

Source of chirality: (S)-prolinol






Absolute configuration: 1*R*,5*S*,2'S $C_{27}H_{36}N_4O_3$ (1*R*,5*R*,13*R*)-13-[(Dimethylamino)methyl]-4-[(2*S*)-(methoxymethyl)pyrrolidinylcarbonyl]-2,8-dimethyl-7-oxo-2,5,6,7-tetrahydro-1*H*-1,5-methano-1*H*-azonino[4,3-*b*]indole $[\alpha]_D^{22} = -83$ (*c* 1.3, CHCl₃)




Source of chirality: (S)-prolinol

Absolute configuration: 1*R*,5*R*,13*R*,2'S $C_{27}H_{38}N_4O_3$ (1*R*,5*R*,7*S*,13*S*)-4-[(2*S*)-(Methoxymethyl)pyrrolidinylcarbonyl]-13-[(dimethylamino)methyl]-7-hydroxy-2,8-dimethyl-2,5,6,7-tetrahydro-1*H*-1,5-methano-1*H*-azonino[4,3-*b*]indole $[\alpha]_D^{22} = -172$ (*c* 0.5, CHCl₃)


Source of chirality: (S)-prolinol

Absolute configuration: 1*R*,5*R*,7*S*,13*S*,2'S


 $[\alpha]_D^{22} = -563$ (*c* 1, CHCl₃)
Source of chirality: (*S*)-prolinolAbsolute configuration: 1*R*,5*R*,7*S*,13*S*(1*R*,5*R*,7*S*,13*S*)-4-Acetyl-13-[(dimethylamino)methyl]-7-hydroxy-2,8-dimethyl-2,5,6,7-tetrahydro-1,5-methano-1*H*-azonino[4,3-*b*]indole
 $[\alpha]_D^{22} = -633$ (*c* 0.4, CHCl₃)
Source of chirality: (*S*)-prolinolAbsolute configuration: 1*R*,5*R*,7*S*(1*R*,5*R*,7*S*)-4-Acetyl-7-hydroxy-2,8-dimethyl-13-methylene-2,5,6,7-tetrahydro-1,5-methano-1*H*-azonino[4,3-*b*]indole(1*R*,5*R*)-4-[(2*S*)-(Methoxymethyl)pyrrolidinylcarbonyl]-2,8-dimethyl-13-methylene-7-oxo-2,5,6,7-tetrahydro-1,5-methano-1*H*-azonino[4,3-*b*]indole
 $[\alpha]_D^{22} = -142$ (*c* 1, CHCl₃)
Source of chirality: (*S*)-prolinolAbsolute configuration: 1*R*,5*R*,2*S*(1*R*,5*R*,7*S*)-7-Hydroxy-2,8-dimethyl-13-methylene-4-[(2*S*)-(methoxymethyl)pyrrolidinylcarbonyl]-2,5,6,7-tetrahydro-1,5-methano-1*H*-azonino[4,3-*b*]indole
 $[\alpha]_D^{22} = -218$ (*c* 0.5, CHCl₃)
Source of chirality: (*S*)-prolinolAbsolute configuration: 1*R*,5*R*,7*S*,2*S*


(1*R*,*S*)-4-Acetyl-2,8-dimethyl-13-methylene-7-oxo-2,5,6,7-tetrahydro-1*H*-azonino[4,3-*b*]indole $[\alpha]_D^{22} = -885$ (*c* 0.5, CHCl₃)Source of chirality: (*S*)-prolinolAbsolute configuration: 1*R*,5*R*(-)- N_a -Methylervitsine $[\alpha]_D^{22} = -60$ (*c* 0.1, CHCl₃)Source of chirality: (*S*)-prolinolAbsolute configuration: 1*R*,5*R*(R)-(+)-2,3,8,9,11,12,12a,17a-Octahydro-17*H*-1,10:4,7-diethenocyclododeca[*a*]fluoren-17-one

E.e. >99%

 $[\alpha]_D^{25} = +346$ (*c* 1.73, CHCl₃)Source of chirality: (*S*)-(+)4-ethenyl[2.2]-paracyclophaneAbsolute configuration: *R*(R)-(+)-13-Methoxy-2,3,8,9,11,12,12a,17a-octahydro-17*H*-1,10:4,7-diethenocyclododeca[*a*]fluoren-17-one

E.e. >99%

 $[\alpha]_D^{25} = +315$ (*c* 0.26, CHCl₃)Source of chirality: (*S*)-(+)4-ethenyl[2.2]-paracyclophane




C₂₈H₂₆O₂

(R)-(+)-14-Methoxy-2,3,8,9,11,12,12a,17a-octahydro-17H-1,10:4,7-diethenocyclododeca[a]fluoren-17-one

E.e. >99%

[α]_D²⁵ = +230 (*c* 0.55, CHCl₃)

Source of chirality: (S)-(+)-4-ethenyl[2.2]-paracyclophane




C₂₈H₂₆O₃

(R)-(+)-15-Methoxy-2,3,8,9,11,12,12a,17a-octahydro-17H-1,10:4,7-diethenocyclododeca[a]fluoren-17-one

E.e. >99%

[α]_D²⁵ = +318 (*c* 1.21, CHCl₃)

Source of chirality: (S)-(+)-4-ethenyl[2.2]-paracyclophane




C₂₉H₂₈O₃

(R)-(+)-13,14-Dimethoxy-2,3,8,9,11,12,12a,17a-octahydro-17H-1,10:4,7-diethenocyclododeca[a]fluoren-17-one

E.e. >99%

[α]_D²⁵ = +323 (*c* 0.50, CHCl₃)

Source of chirality: (S)-(+)-4-ethenyl[2.2]-paracyclophane




C₂₉H₂₈O₃

(R)-(+)-14,15-Dimethoxy-2,3,8,9,11,12,12a,17a-octahydro-17H-1,10:4,7-diethenocyclododeca[a]fluoren-17-one

E.e. >99%

[α]_D²⁵ = +302 (*c* 0.20, CHCl₃)

Source of chirality: (S)-(+)-4-ethenyl[2.2]-paracyclophane




C₂₇H₂₀O

(R)-(+)-2,3,8,9-Tetrahydro-17H-1,10:4,7-diethenocyclododeca[a]fluoren-17-one

E.e. >99%

[α]_D²⁵ = +1273 (*c* 0.35, CHCl₃)

Source of chirality: (S)-(+)-4-ethenyl[2.2]-paracyclophane




C₂₈H₂₂O₂

(R)-(+)-13-Methoxy-2,3,8,9-tetrahydro-17H-1,10:4,7-diethenocyclododeca[a]fluoren-17-one

E.e. >99%

[α]_D²⁵ = +1314 (*c* 0.16, CHCl₃)

Source of chirality: (S)-(+)-4-ethenyl[2.2]-paracyclophane




C₂₈H₂₂O₂

(R)-(+)-14-Methoxy-2,3,8,9-tetrahydro-17H-1,10:4,7-diethenocyclododeca[a]fluoren-17-one

E.e. >99%

[α]_D²⁵ = +1093 (*c* 0.59, CHCl₃)

Source of chirality: (S)-(+)-4-ethenyl[2.2]-paracyclophane




C₂₈H₂₂O₂

(R)-(+)-15-Methoxy-2,3,8,9-tetrahydro-17H-1,10:4,7-diethenocyclododeca[a]fluoren-17-one

E.e. >99%

[α]_D²⁵ = +1692 (*c* 0.15, CHCl₃)

Source of chirality: (S)-(+)-4-ethenyl[2.2]-paracyclophane




(*R*)-(+)-13,14-Dimethoxy-2,3,8,9-tetrahydro-17*H*-1,10:4,7-diethenocyclododeca[*a*]fluoren-17-one

E.e. >99%

$[\alpha]_D^{25} = +1040$ (*c* 0.45, CHCl₃)

Source of chirality: (*S*)-(+)-4-ethenyl[2.2]-paracyclophane




(*R*)-(+)-14,15-Dimethoxy-2,3,8,9-tetrahydro-17*H*-1,10:4,7-diethenocyclododeca[*a*]fluoren-17-one

E.e. >99%

$[\alpha]_D^{25} = +1952$ (*c* 0.14, CHCl₃)

Source of chirality: (*S*)-(+)-4-ethenyl[2.2]-paracyclophane




[2S,1'S,2'S]-(+)-2-(3,4-Dimethoxyphenyl)-3-hydroxy-N-methyl-N-(2'-phenyl-2'-hydroxy-1'-methylethyl)propanamide

$[\alpha]_D^{20} = +31.2$ (*c* 0.7, CH₂Cl₂)

Source of chirality: (*S,S*)-(+)-pseudoephedrine

Absolute configuration: 2*S*,1'*S*,2'*S*




[2S,1'S,2'S]-(+)-3-Hydroxy-N-methyl-N-(2'-phenyl-2'-hydroxy-1'-methylethyl)-2-(3,4,5-trimethoxyphenyl)propanamide




$[\alpha]_D^{20} = +69.4$ (*c* 0.3, CH₂Cl₂)


Source of chirality: (*S,S*)-(+)-pseudoephedrine

Absolute configuration: 2*S*,1'*S*,2'*S*


 $C_{20}H_{23}NO_5$

[2S,1'S,2'S]-(+)-3-Hydroxy-N-methyl-2-(3,4-methylenedioxyphenyl)-N-(2'-phenyl-2'-hydroxy-1'-methylethyl)propanamide


 $[\alpha]_D^{20} = +55.6$ (*c* 0.3, CH_2Cl_2)Source of chirality: (*S,S*)-(+)-pseudoephedrineAbsolute configuration: 2*S*,1'*S*,2'*S* $C_{18}H_{20}O_6$ [2*S*]-(+)-2-(3,4-Dimethoxyphenyl)-3-(4-methoxyphenoxy)propanoic acid $[\alpha]_D^{20} = +23.5$ (*c* 0.1, CH_2Cl_2)Source of chirality: (*S,S*)-(+)-pseudoephedrineAbsolute configuration: 2*S* $C_{19}H_{22}O_7$ [2*S*]-(+)-3-(4-Methoxyphenoxy)-2-(3,4,5-trimethoxyphenyl)propanoic acid $[\alpha]_D^{20} = +21.8$ (*c* 0.1, CH_2Cl_2)Source of chirality: (*S,S*)-(+)-pseudoephedrineAbsolute configuration: 2*S* $C_{17}H_{16}O_6$ [2*S*]-(+)-3-(4-Methoxyphenoxy)-2-(3,4-methylenedioxyphenyl)propanoic acid $[\alpha]_D^{20} = +33.4$ (*c* 0.1, CH_2Cl_2)Source of chirality: (*S,S*)-(+)-pseudoephedrineAbsolute configuration: 2*S*

 $C_{19}H_{22}O_7$


[2S]-(+)-2-(3,4-Dimethoxyphenyl)-3-(3,5-dimethoxyphenoxy)propanoic acid

 $[\alpha]_D^{20} = +41.3$ (*c* 0.1, CH_2Cl_2)Source of chirality: (*S,S*)-(+)pseudoephedrineAbsolute configuration: 2*S* $C_{18}H_{18}O_5$

[2S]-(+)-3',4',6-Trimethoxyisoflavanone


 $[\alpha]_D^{20} = +51.8$ (*c* 0.1, CH_2Cl_2)Source of chirality: (*S,S*)-(+)pseudoephedrineAbsolute configuration: 2*S* $C_{19}H_{20}O_6$

[2S]-(+)-3',4',5',6-Tetramethoxyisoflavanone




 $[\alpha]_D^{20} = +64.4$ (*c* 0.2, CH_2Cl_2)Source of chirality: (*S,S*)-(+)pseudoephedrineAbsolute configuration: 2*S* $C_{17}H_{14}O_5$


[2S]-(+)-6-Methoxy-3',4'-methylenedioxyisoflavanone

 $[\alpha]_D^{20} = +58.3$ (*c* 0.2, CH_2Cl_2)Source of chirality: (*S,S*)-(+)pseudoephedrineAbsolute configuration: 2*S*

 $C_{19}H_{20}O_6$

[2S]-(+)-3',4',5,7-Tetramethoxyisoflavanone

 $[\alpha]_D^{20} = +54.6$ (*c* 0.2, CH_2Cl_2)Source of chirality: (*S,S*)-(+)pseudoephedrineAbsolute configuration: 2*S* $C_{14}H_{20}N_2O$ trans-($\alpha R,1S,2S$)-2-Methyl-1-(1-phenylethylamino)cyclobutanecarboxamide $[\alpha]_D^{25} = +61.9$ (*c* 0.88, methanol)Source of chirality: (*R*)-1-phenylethylamineAbsolute configuration: $\alpha R,1S,2S$  $C_{14}H_{20}N_2O$ trans-($\alpha R,1R,2R$)-2-Methyl-1-(1-phenylethylamino)cyclobutanecarboxamide $[\alpha]_D^{25} = -19.3$ (*c* 0.85, methanol)Source of chirality: (*R*)-1-phenylethylamineAbsolute configuration: $\alpha R,1R,2R$  $C_{14}H_{20}N_2O$ cis-($\alpha R,1R,2S$)-2-Methyl-1-(1-phenylethylamino)cyclobutanecarboxamide $[\alpha]_D^{25} = +2.6$ (*c* 0.74, methanol)Source of chirality: (*R*)-1-phenylethylamineAbsolute configuration: $\alpha R,1R,2S$





cis-(α S,1S,2R)-2-Methyl-1-(1-phenylethylamino)cyclobutanecarboxamide

$[\alpha]_D^{25} = -3.0$ (*c* 1.01, methanol)

Source of chirality: (*S*)-1-phenylethylamine

Absolute configuration: α S,1S,2R





trans-(1S,2S)-1-Amino-2-methylcyclobutanecarboxamide hydrochloride

$[\alpha]_D^{25} = +86.1$ (*c* 1.02, methanol)

Source of chirality: (*R*)-1-phenylethylamine

Absolute configuration: 1S,2S





trans-(1R,2R)-1-Amino-2-methylcyclobutanecarboxamide hydrochloride

$[\alpha]_D^{25} = -86.8$ (*c* 0.88, methanol)

Source of chirality: (*R*)-1-phenylethylamine

Absolute configuration: 1R,2R











cis-(1R,2S)-1-Amino-2-methylcyclobutanecarboxamide hydrochloride

$[\alpha]_D^{25} = +7.1$ (*c* 1.03, methanol)



Source of chirality: (*R*)-1-phenylethylamine

Absolute configuration: 1R,2S


*cis*-(1*S*,2*R*)-1-Amino-2-methylcyclobutanecarboxamide hydrochloride
 $[\alpha]_D^{25} = -7.4$ (*c* 1.02, methanol)
Source of chirality: (*S*)-1-phenylethylamineAbsolute configuration: 1*S*,2*R**trans*-(1*S*,2*S*)-1-Amino-2-methylcyclobutanecarboxylic acid hydrochloride
 $[\alpha]_D^{25} = +13.8$ (*c* 0.11, water)
Source of chirality: (*R*)-1-phenylethylamineAbsolute configuration: 1*S*,2*S**trans*-(1*R*,2*R*)-1-Amino-2-methylcyclobutanecarboxylic acid hydrochloride
 $[\alpha]_D^{25} = -14.5$ (*c* 0.10, water)
Source of chirality: (*R*)-1-phenylethylamineAbsolute configuration: 1*R*,2*R**cis*-(1*R*,2*S*)-1-Amino-2-methylcyclobutanecarboxylic acid hydrochloride
 $[\alpha]_D^{25} = +23.5$ (*c* 0.19, water)
Source of chirality: (*R*)-1-phenylethylamineAbsolute configuration: 1*R*,2*S*




cis-(1S,2R)-1-Amino-2-methylcyclobutanecarboxylic acid hydrochloride

 $[\alpha]_D^{25} = -24.0 \text{ (} c \text{ 0.09, water)}$
Source of chirality: (*S*)-1-phenylethylamineAbsolute configuration: 1*S*,2*R*(1*R*)-1-Naphthalen-1-ylethane-1,2-diol
 $[\alpha]_D^{20} = -84.0 \text{ (} c \text{ 0.11, CHCl}_3)$

Source of chirality: Sharpless' asymmetric dihydroxylation


Absolute configuration: 1*R*(1*R*)-1-Naphthalen-2-ylethane-1,2-diol
 $[\alpha]_D^{20} = -47.1 \text{ (} c \text{ 0.07, CHCl}_3)$

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 1*R*(1*R*)-1-Phenylethane-1,2-diol
 $[\alpha]_D^{20} = -62.7 \text{ (} c \text{ 0.11, CHCl}_3)$

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 1*R*




(2*R*)-3,3,3-Trifluoro-2-phenylpropane-1,2-diol

[α]_D²⁰ = -18.0 (*c* 0.35, CH₃OH)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 2*R*




(1*R*)-2-(*tert*-Butyldimethylsilyloxy)-1-naphthalen-1-ylethanol

[α]_D²⁰ = -40.2 (*c* 0.09, CHCl₃)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 1*R*




(1*R*)-2-(*tert*-Butyldimethylsilyloxy)-1-naphthalen-2-ylethanol

[α]_D²⁰ = -31.9 (*c* 0.48, CHCl₃)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 1*R*




(1*R*)-2-(*tert*-Butyldimethylsilyloxy)-1-phenylethanol

[α]_D²⁰ = -28.2 (*c* 0.11, CHCl₃)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 1*R*




C₁₅H₂₃F₃O₂Si

(2*R*)-3-(*tert*-Butyldimethylsilyloxy)-1,1,1-trifluoro-2-phenylpropan-2-ol

[α]_D²⁰ = -9.7 (*c* 0.26, CHCl₃)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 2*R*




C₁₉H₂₈O₂Si

(1*R*)-2-(*tert*-Butyldimethylsilyloxy)-1-methoxy-1-naphthalen-1-ylethane

[α]_D²⁰ = -85.5 (*c* 0.11, CHCl₃)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 1*R*




C₁₉H₂₈O₂Si

(1*R*)-2-(*tert*-Butyldimethylsilyloxy)-1-methoxy-1-naphthalen-2-ylethane

[α]_D²⁰ = -46.7 (*c* 0.91, CHCl₃)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 1*R*




C₁₅H₂₆O₂Si

(1*R*)-2-(*tert*-Butyldimethylsilyloxy)-1-methoxy-1-phenylethane

[α]_D²⁰ = -51.2 (*c* 0.21, CHCl₃)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 1*R*




C₁₆H₂₅F₃O₂Si
(2*R*)-3-(*tert*-Butyldimethylsilyloxy)-1,1,1-trifluoro-2-methoxy-2-phenylpropane

[α]_D²⁰ = +3.0 (*c* 0.29, CHCl₃)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 2*R*




C₁₃H₁₄O₂
(2*R*)-2-Methoxy-2-naphthalen-1-ylethanol

[α]_D²⁰ = -122.3 (*c* 0.11, CHCl₃)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 2*R*




C₁₃H₁₄O₂
(2*R*)-2-Methoxy-2-naphthalen-2-ylethanol

[α]_D²⁰ = -123.2 (*c* 0.74, CHCl₃)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 2*R*




C₉H₁₂O₂
(2*R*)-2-Methoxy-2-phenylethanol

[α]_D²⁰ = -99.0 (*c* 0.10, CHCl₃)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 2*R*




C₁₀H₁₁F₃O₂
(2R)-3,3-Trifluoro-2-methoxy-2-phenylpropanol

[α]_D²⁰ = -17.9 (*c* 0.35, CHCl₃)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 2*R*




C₁₃H₁₂O₃
(2R)- α -Methoxynaphthalen-1-ylacetic acid

[α]_D²⁰ = -132.6 (*c* 0.10, EtOH)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 2*R*




C₁₃H₁₂O₃
(2R)- α -Methoxynaphthalen-2-ylacetic acid

[α]_D²⁰ = -133.0 (*c* 0.01, EtOH)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 2*R*




C₉H₁₀O₃
(2R)- α -Methoxyphenylacetic acid

[α]_D²⁰ = -144.0 (*c* 1.03, EtOH)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 2*R*




(2*R*)- α -Methoxy- α -(trifluoromethyl)phenylacetic acid

[α]_D²⁰ = +69.8 (*c* 0.22, EtOH)

Source of chirality: Sharpless' asymmetric dihydroxylation

Absolute configuration: 2*R*




1,1'-Bis((*R*)-1,3-diphenyl-2-propenyl)ferrocene

E.e. >99% (by preparation method)

[α]_D²⁰ = -249 (*c* 1.0, CHCl₃)

Source of chirality: chiral catalyst

Absolute configuration: *R,R*





1,1'-Bis((*R*)-1,3-diphenyl-2-propenyl)zirconocene dichloride

E.e. >99% (by preparation method)

[α]_D²⁰ = -119 (*c* 1.0, CHCl₃)

Source of chirality: chiral catalyst

Absolute configuration: *R,R*




1,1'-Bis((*R*)-1,3-diphenyl-2-propenyl)titanocene dichloride

E.e. >99% (by preparation method)


[α]_D²⁰ = +133 (*c* 1.0, CHCl₃)

Source of chirality: chiral catalyst


Absolute configuration: *R,R*

 $C_{17}H_{24}N_2O_4$


(2'S,3'R,5S,6R)-3,4,5,6-Tetrahydro-3-(3-hydroxy-2-methylpentanoyl)-4,5-dimethyl-6-phenyl-1,3,4-oxadiazin-2-one

 $[\alpha]_D^{25} = +5.2$ (*c* 0.97, MeOH)Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: 2'S,3'R,5S,6*R* $C_{18}H_{26}N_2O_4$

(2'S,3'R,5S,6R)-3,4,5,6-Tetrahydro-3-(3-hydroxy-2,4-dimethylpentanoyl)-4,5-dimethyl-6-phenyl-1,3,4-oxadiazin-2-one


 $[\alpha]_D^{24} = +7.4$ (*c* 1.02, MeOH)Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: 2'S,3'R,5S,6*R* $C_{21}H_{30}N_2O_4$

(2'S,3'R,5S,6R)-3-(3-Cyclohexyl-3-hydroxy-2-methylpropionyl)-3,4,5,6-tetrahydro-4,5-dimethyl-6-phenyl-1,3,4-oxadiazin-2-one

 $[\alpha]_D^{24} = +3.0$ (*c* 1.20, MeOH)Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: 2'S,3'R,5S,6*R* $C_{23}H_{28}N_2O_5$

(2'S,3'R,5S,6R)-3-(4-Benzylxyloxy-3-hydroxy-2-methylbutyryl)-3,4,5,6-tetrahydro-4,5-dimethyl-6-phenyl-1,3,4-oxadiazin-2-one

 $[\alpha]_D^{24} = -1.3$ (*c* 0.98, MeOH)Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: 2'S,3'R,5S,6*R*

 $[\alpha]_D^{24} = -2.3$ (*c* 1.00, MeOH)Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: 2'*S*,3'*R*,5*S*,6*R* $C_{23}H_{26}N_2O_4$ (2'*S*,3'*R*,5*S*,6*R*)-3-(3-Hydroxy-2-methyl-5-phenylpent-4-enoyl)-4,5-dimethyl-6-phenyl-[1,3,4]oxadiazinan-2-one